Klas Wiman and Sören Lehmann abstract
A large fraction of human tumors carry mutant p53 and activation of mutant p53 constitutes an attractive treatment strategy for cancer. We have previously discovered an activator of mutant p53, PRIMA-1. Its methylated form, PRIMA-1MET or APR-246, has now been tested in a first-in-man phase I/II trial in therapy-resistant hematological malignancies and prostate cancer. APR-246 showed a favorable safety and pharmacokinetic profile, and induced relevant biological effects such as increased apoptosis and up-regulation of p53 target genes, as well as examples of clinical responses.
At the Karolinska Institutet Discovers seminar professor Klas Wiman and associate professor Sören Lehmann present the research behind their recent publication:
J Clin Oncol September 2012
Lehmann S, Bykov VJN, Ali D, Andrén O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG, Andersson P-O.